Published in Ann Intern Med on November 15, 2005
Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med (2011) 1.69
JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab (2010) 1.10
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol (2010) 1.01
Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2011) 0.89
Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med (2012) 0.79
Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.78
A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol (2007) 0.77
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2005) 6.23
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol (2009) 2.30
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology (2005) 2.02
Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology (2009) 1.84
Steatosis: co-factor in other liver diseases. Hepatology (2005) 1.76
Ductular reactions in human liver: diversity at the interface. Hepatology (2011) 1.70
IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood (2007) 1.59
Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging (2008) 1.56
Type I-IFNs control GVHD and GVL responses after transplantation. Blood (2011) 1.54
Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol (2005) 1.53
Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood (2009) 1.50
Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res (2008) 1.50
Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology (2009) 1.47
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 1.34
TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood (2005) 1.31
In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol (2003) 1.29
GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology (2010) 1.25
Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology (2004) 1.25
Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood (2010) 1.24
The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology (2014) 1.24
Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood (2006) 1.17
Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology (2005) 1.17
Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol (2003) 1.13
Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood (2012) 1.12
Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood (2004) 1.09
Obesity management in liver clinics: translation of research into clinical practice. J Gastroenterol Hepatol (2007) 1.07
Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl (2009) 1.05
Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol (2003) 1.05
Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol (2005) 1.04
Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology (2008) 1.04
Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol (2013) 0.98
Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer (2008) 0.97
Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest (2013) 0.96
Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology (2011) 0.95
Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut (2012) 0.94
Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma. PLoS One (2011) 0.94
Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol (2002) 0.92
Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol (2008) 0.92
The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis. Liver Int (2012) 0.92
Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood (2013) 0.90
SOCS3 regulates graft-versus-host disease. Blood (2010) 0.89
Virus-specific CD8+ T lymphocytes within the normal human liver. Eur J Immunol (2004) 0.89
Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. Am J Physiol Gastrointest Liver Physiol (2011) 0.87
Hepatic progenitor cell-mediated regeneration and fibrosis: chicken or egg? Hepatology (2009) 0.86
Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis (2010) 0.86
Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver Int (2012) 0.86
CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest (2014) 0.85
Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis (2007) 0.84
Pathology of the liver sinusoids. Histopathology (2014) 0.83
Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics (2004) 0.83
Lymphocyte apoptosis and cell replacement in human liver allografts. Transplantation (2002) 0.82
Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. Mol Diagn Ther (2008) 0.82
Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. Blood (2009) 0.82
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. Biol Blood Marrow Transplant (2004) 0.80
Ductular reaction in hereditary hemochromatosis: the link between hepatocyte senescence and fibrosis progression. Hepatology (2014) 0.80
Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Ann Nucl Med (2009) 0.80
BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. Alcohol Clin Exp Res (2013) 0.79
Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. J Gastroenterol Hepatol (2003) 0.79
No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol (2011) 0.79